• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

3 年性别肯定激素治疗后的持续乳房发育和乳房人体测量学变化。

Sustained Breast Development and Breast Anthropometric Changes in 3 Years of Gender-Affirming Hormone Treatment.

机构信息

Department of Endocrinology, Amsterdam UMC, VU University Medical Center, HV, Amsterdam, the Netherlands.

Center of Expertise on Gender Dysphoria, Amsterdam UMC, VU University Medical Center, HV, Amsterdam, the Netherlands.

出版信息

J Clin Endocrinol Metab. 2021 Jan 23;106(2):e782-e790. doi: 10.1210/clinem/dgaa841.

DOI:10.1210/clinem/dgaa841
PMID:33206172
Abstract

CONTEXT

Breast development is important for most trans women. An important limitation of current breast development measurement methods is that these do not allow for 3D volume analyses.

OBJECTIVES

To examine breast development and change in anthropometry during the first 3 years of gender-affirming hormone treatment using 3D imaging. Associations with clinical or laboratory parameters and satisfaction with the gained breast development were also studied.

DESIGN

Prospective cohort study.

SETTING

Specialized tertiary gender identity clinic in Amsterdam, the Netherlands.

PARTICIPANTS

Participants were 69 adult trans women with a median age of 26 years (interquartile range, 21-38).

INTERVENTIONS

Gender-affirming hormone treatment.

MAIN OUTCOME MEASURES

Volumetric and anthropometric breast development and satisfaction.

RESULTS

Breast volume increased by 72 cc (95% confidence interval [CI], 48-97) to 100 cc (standard deviation 48). This resulted in a cup-size <A-cup in 71% of the participants. Although the change in breast-chest difference plateaued after approximately 9 months, sustained increase in breast volume was observed during the 3-year observation period. Sternal notch to nipple distance increased by 1.3 cm (95% CI, 0.9-1.7) and internipple distance increased by 1.0 cm (95% CI, 0.4-1.5). At least 58% of trans women were satisfied with the gained breast size.

CONCLUSIONS

Sustained breast growth and development during hormone treatment was observed during the full 3-year observation period. The breasts of trans women are positioned more laterally and caudally on the chest compared with cis women. Although modest breast volumes were observed, breast development was satisfactory to most trans women.

摘要

背景

乳房发育对大多数跨性别女性而言非常重要。当前乳房发育测量方法的一个重要局限性在于无法进行 3D 体积分析。

目的

使用 3D 成像技术,研究在接受性别肯定激素治疗的前 3 年内乳房发育和人体测量学的变化,并探讨其与临床或实验室参数的相关性以及对获得的乳房发育的满意度。

设计

前瞻性队列研究。

地点

荷兰阿姆斯特丹的一家专门的三级性别认同诊所。

参与者

69 名年龄中位数为 26 岁(四分位距 21-38 岁)的成年跨性别女性。

干预措施

性别肯定激素治疗。

主要观察指标

体积和人体测量学乳房发育和满意度。

结果

乳房体积增加了 72cc(95%置信区间:48-97)至 100cc(标准差为 48),这使得 71%的参与者的罩杯尺寸< A 罩杯。尽管乳房-胸部差异的变化在大约 9 个月后趋于平稳,但在 3 年的观察期间仍观察到乳房体积持续增加。胸骨切迹到乳头的距离增加了 1.3cm(95%置信区间:0.9-1.7),乳头间距离增加了 1.0cm(95%置信区间:0.4-1.5)。至少有 58%的跨性别女性对获得的乳房大小感到满意。

结论

在整个 3 年的观察期间,激素治疗期间持续观察到乳房生长和发育。与 cis 女性相比,跨性别女性的乳房在胸部更偏向外侧和尾部。尽管观察到乳房体积较小,但乳房发育对大多数跨性别女性而言是满意的。

相似文献

1
Sustained Breast Development and Breast Anthropometric Changes in 3 Years of Gender-Affirming Hormone Treatment.3 年性别肯定激素治疗后的持续乳房发育和乳房人体测量学变化。
J Clin Endocrinol Metab. 2021 Jan 23;106(2):e782-e790. doi: 10.1210/clinem/dgaa841.
2
Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands.接受激素治疗的跨性别者的乳腺癌风险:荷兰全国队列研究。
BMJ. 2019 May 14;365:l1652. doi: 10.1136/bmj.l1652.
3
Breast Development in Transwomen After 1 Year of Cross-Sex Hormone Therapy: Results of a Prospective Multicenter Study.跨性别女性接受跨性别激素治疗 1 年后的乳房发育:一项前瞻性多中心研究的结果。
J Clin Endocrinol Metab. 2018 Feb 1;103(2):532-538. doi: 10.1210/jc.2017-01927.
4
Muscle Strength, Size, and Composition Following 12 Months of Gender-affirming Treatment in Transgender Individuals.跨性别个体接受性别肯定治疗 12 个月后的肌肉力量、大小和组成。
J Clin Endocrinol Metab. 2020 Mar 1;105(3). doi: 10.1210/clinem/dgz247.
5
Prostate Cancer Incidence under Androgen Deprivation: Nationwide Cohort Study in Trans Women Receiving Hormone Treatment.雄激素剥夺治疗下的前列腺癌发病率:接受激素治疗的跨性别女性的全国队列研究。
J Clin Endocrinol Metab. 2020 Sep 1;105(9):e3293-9. doi: 10.1210/clinem/dgaa412.
6
The Role of Estrone in Feminizing Hormone Treatment.雌酮在女性激素治疗中的作用。
J Clin Endocrinol Metab. 2022 Jan 18;107(2):e458-e466. doi: 10.1210/clinem/dgab741.
7
Frequency and outcomes of benign breast biopsies in trans women: A nationwide cohort study.跨性别女性良性乳腺活检的频率和结果:一项全国性队列研究。
Breast. 2021 Jun;57:118-122. doi: 10.1016/j.breast.2021.03.007. Epub 2021 Mar 25.
8
The Amsterdam Cohort of Gender Dysphoria Study (1972-2015): Trends in Prevalence, Treatment, and Regrets.阿姆斯特丹性别焦虑症队列研究(1972-2015):患病率、治疗方法和后悔率的趋势。
J Sex Med. 2018 Apr;15(4):582-590. doi: 10.1016/j.jsxm.2018.01.016. Epub 2018 Feb 17.
9
Incidence of High Risk and Malignant Pathological Findings in Transgender and Gender Diverse Individuals Undergoing Gender-Affirming Mastectomy. transgender 和性别多样化个体行性别肯定乳房切除术的高风险和恶性病理发现的发生率。
Ann Surg Oncol. 2024 Nov;31(12):8086-8092. doi: 10.1245/s10434-024-16005-1. Epub 2024 Aug 7.
10
Gender-affirming hormone treatment and cognitive function in transgender young adults: a systematic review and meta-analysis.性别肯定激素治疗与跨性别青年认知功能:系统评价和荟萃分析。
Psychoneuroendocrinology. 2020 Sep;119:104721. doi: 10.1016/j.psyneuen.2020.104721. Epub 2020 May 31.

引用本文的文献

1
Endocrine issues in critically ill transgender patients: A narrative review.危重症跨性别患者的内分泌问题:一项叙述性综述。
World J Crit Care Med. 2025 Sep 9;14(3):100660. doi: 10.5492/wjccm.v14.i3.100660.
2
Improving care for individuals with gender incongruence: Establishing a multidisciplinary approach in Italy.改善对性别认同障碍者的护理:在意大利建立多学科方法。
J Endocrinol Invest. 2025 Jun 6. doi: 10.1007/s40618-025-02580-x.
3
Breast care considerations for transgender and gender-diverse patients.跨性别和性别多样化患者的乳房保健注意事项。
Womens Health (Lond). 2024 Jan-Dec;20:17455057241289706. doi: 10.1177/17455057241289706.
4
Effect of Spironolactone and Cyproterone Acetate on Breast Growth in Transgender People: A Randomized Clinical Trial.螺内酯和醋酸环丙孕酮对跨性别者乳房发育的影响:一项随机临床试验。
J Clin Endocrinol Metab. 2025 May 19;110(6):e1874-e1884. doi: 10.1210/clinem/dgae650.
5
Validation of Breast Idea Volume Estimator Application in Transfeminine People.女性化人群中乳房Idea体积估计器应用的验证
Plast Reconstr Surg Glob Open. 2024 Sep 3;12(9):e6131. doi: 10.1097/GOX.0000000000006131. eCollection 2024 Sep.
6
Shaping the Skeleton: Impact of GnRH Analogue and Sex Hormone Therapy on Skeletal Dimensions in Transgender Individuals.塑造骨骼:促性腺激素释放激素类似物和性激素疗法对跨性别者骨骼尺寸的影响
J Clin Endocrinol Metab. 2025 Apr 22;110(5):e1411-e1419. doi: 10.1210/clinem/dgae574.
7
Variations in Volume: Breast Size in Trans Women in Relation to Timing of Testosterone Suppression.体积变化:接受睾酮抑制治疗时间与跨性别女性乳房大小的关系
J Clin Endocrinol Metab. 2025 Apr 22;110(5):e1404-e1410. doi: 10.1210/clinem/dgae573.
8
A comparative study of 3D measuring methods for monitoring breast volume changes.3D 测量方法在监测乳房体积变化中的对比研究。
PLoS One. 2024 Jun 6;19(6):e0305059. doi: 10.1371/journal.pone.0305059. eCollection 2024.
9
Priorities for efficacy trials of gender-affirming hormone therapy with estrogen: collaborative design and results of a community survey.具有雌激素的性别肯定激素治疗功效试验的优先事项:社区调查的协作设计和结果。
Hormones (Athens). 2024 Jun;23(2):287-295. doi: 10.1007/s42000-024-00532-3. Epub 2024 Feb 5.
10
Addition of progesterone to feminizing gender-affirming hormone therapy in transgender individuals for breast development: a randomized controlled trial.为促进 transgender 个体的乳房发育,在女性化性别肯定激素治疗中添加孕激素:一项随机对照试验。
BMC Pharmacol Toxicol. 2023 Dec 20;24(1):80. doi: 10.1186/s40360-023-00724-4.